ArticleJournal of oncology2014
Predictors of venous thromboembolic events associated with central venous port insertion in cancer patients.
Article in Journal of oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.Thrombosis and haemostasis · 2017Trial
- Machine learning survival model for personalised prevention of catheter-related thrombosis in tumour patients.Communications medicine · 2026Article
- Construction and verification of a nomogram to predict the probability of venous thromboembolism in lung cancer patients.Frontiers in molecular biosciences · 2026Article
- Article
- Application of pocket-first technique for implantation of totally implantable venous access ports.BMC surgery · 2024Article
- Risk factors for totally implantable access ports-associated thrombosis in pediatric oncology patients.Scientific reports · 2023Article
- Risk Factors and Prediction Models for Venous Thromboembolism in Ambulatory Patients with Lung Cancer.Healthcare (Basel, Switzerland) · 2021Review
- Utilization and Complications of Central Venous Access Devices in Oncology Patients.Current oncology (Toronto, Ont.) · 2021Article
- Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels.Cancer medicine · 2020Article
- Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis Based on Vascular Ultrasound Diagnosis in Cancer Patients.Frontiers in cardiovascular medicine · 2020Article
- Cancer and Venous Thromboembolic Disease: A Review.The oncologist · 2017Review
- Implantable port thrombosis in cancer patients: a monocentric experience.Cancer biology & medicine · 2016Article
- Femoral Placement of Totally Implantable Venous Access Ports in Patients with Bilateral Breast Cancer.Geburtshilfe und Frauenheilkunde · 2016Article
- Performance of venous port catheter insertion by a general surgeon: a prospective study.International surgery · 2015Article
- Antiphospholipid antibodies in patients with upper-extremity deep vein thrombosis.Central-European journal of immunology · 2015Article
- Incidence and Timing of Venous Thromboembolism After Implantable Port Placement in Cancer Patients: A Single-Centre Cohort Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insertion of central venous port (CVP) catheter in the cancer population is associated with increased incidence of venous thromboembolic events (VTE). However, trials have shown limited benefit of antithrombotic treatment to prevent catheter-related venous thrombosis. This prospective observational cohort study was designed to assess the incidence of VTE closely related to CVP implantation in patients with cancer and undergoing chemotherapy, and to identify a high risk subgroup of patients. Between February 2006 and December 2011, 1097 consecutive cancer patients with first CVP implantation were included. Catheter-related VTE were defined as deep venous thrombosis in the arm, with or without pulmonary embolism (PE), or isolated PE. The incidence of CVP-associated VTE was 5.9% (IC95 4.4-7.3%) at 3 months, and 11.3% (IC95 9.4-13.2%) at 12 months. The incidence of any VTE was 7.6% (IC95 6.0-9.3%) at 3 months, and 15.3% (IC95 13.1-17.6%) at 12 months. High Khorana risk score and lung cancer were significant predictors of 3 month VTE. In conclusion, this large cohort study of patients with first CVP catheter implantation confirms the high incidence of VTE associated with the CVP implantation and allow identifying high risk patients who may benefit from thromboprophylaxis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.